Filing Details

Accession Number:
0001127602-19-033709
Form Type:
4
Zero Holdings:
No
Publication Time:
2019-11-25 18:27:17
Reporting Period:
2019-11-25
Accepted Time:
2019-11-25 18:27:17
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
318154 Amgen Inc AMGN Biological Products, (No Disgnostic Substances) (2836) 953540776
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1444612 W David Meline One Amgen Center Drive
Thousand Oaks CA 91320-1799
Evp & Cfo No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2019-11-25 8,737 $234.36 49,378 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Direct
Footnotes
  1. These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 1,523 RSUs which vest in one installment on 5/3/2020; 2,885 RSUs which vest in installments of 1,421 on 5/1/2020 and 1,464 on 5/1/2021; 4,508 RSUs which vest in installments of 1,487 on 4/27/2020, 1,488 on 4/27/2021 and 1,533 on 4/27/2022; and 4,511 which will vest in installments of 1,488 on 5/3/2021, 1,489 on 5/3/2022 and 1,534 on 5/3/2023. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.
  2. These shares include 637 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting persons' unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.